Fortress Biotech, Inc.

NASDAQ:FBIO

Biotechnology

Healthcare
$1.89 -1.79%

-$0.06 today

Market cap
$63.03M
Beta
1.23
P/E (TTM)
0.7
EPS (TTM)
$4.05
52W Low $1.70High $4.53

Volume 0.41M

Average 0.43M

FBIO Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Fortress Biotech, Inc.NASDAQ: FBIO

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 10.0% from a year ago

Common stock stood at $33K at the end of Q1 FY2026, up 10.0% from a year earlier and up 3.1% from the prior quarter. Over 3 fiscal years it compounded at -33.7% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 2 of the last 3 fiscal years.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +10.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33K+3.1% QoQ
Last fiscal yearDec 2025
$32K+14.3% YoY
Year agoMar 2025
$30K+10.0% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.0%——
1 year+14.3%——
3-year CAGR-33.7%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
32K USD
Year-over-year change
+14.3%
4-year CAGR
-25.0%

Common Stock vs competitors

How FBIO compares with its peers on the latest reported figures

  • FBIO's Mar 2026 common stock of $33K is the 3rd highest of the 10 companies compared; the peer median is $11K.
  • Its year-over-year change of +10.0% is the 4th highest of 9, against a peer median of +6.8%.
  • Common stock amounts to 0.0% of total assets for FBIO, versus a peer median of 0.0%.
FBIO Competitors Peer median
Common Stock for FBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
XBITXBiotech Inc.Mar 2026$276.9M +0.2%+1.2%198.0%
RLMDRelmada Therapeutics, Inc.Mar 2026$104.89K +216.0%+34.6%0.0%
FBIOFortress Biotech, Inc.Mar 2026$33K +10.0%-33.7%0.0%
VXRTVaxart, Inc.Mar 2026$24K +4.3%+22.7%0.0%
NTRBNutriband Inc.Apr 2026$12.16K +9.2%+15.8%0.2%
IMUXImmunic, Inc.Mar 2026$11K +37.5%+31.0%0.0%
TCRXTScan Therapeutics, Inc.Mar 2026$6K +0.0%+18.6%0.0%
ADAGAdagene Inc.Dec 2025$5.92K +0.6%+2.5%0.0%
GANXGain Therapeutics, Inc.Mar 2026$4.25K +47.8%+52.4%0.0%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
Peer median (excluding FBIO) $11K+6.8%+20.6%0.0%

Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents305.74M178.27M80.93M57.26M79.38M
Short-term Investments00000
Net Receivables23.79M28.35M15.39M10.4M29.94M
Inventory9.86M14.16M10.21M14.43M9.62M
Other Current Assets09.66M10.5M8.28M5.05M
Total Current Assets346.46M230.43M117.02M90.37M123.84M
Property, Plant & Equipment (Net)34.07M33.01M23.5M17.12M14.82M
Goodwill00000
Intangible Assets12.55M27.2M20.29M31.86M27.61M
Long-term Investments2.22M2.69M2.44M1.55M17.66M
Tax Assets(2.22M)(2.69M)000
Other Non-current Assets3.42M3.66M4.28M3.32M1.62M
Total Non-current Assets50.04M63.87M50.5M53.85M61.71M
Total Assets396.5M294.3M167.53M144.22M185.55M
Account Payables47.43M57.24M34.81M31.64M14.24M
Short-term Debt5.32M10.18M3M625K0
Tax Payables345K722K843K932K356K
Deferred Revenue2.61M728K000
Other Current Liabilities34.42M46.62M9.06M4.84M2.31M
Total Current Liabilities101.04M127.72M84.91M71.4M49.74M
Long-term Debt46.56M93.14M60.86M57.96M59.5M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.03M1.85M1.89M1.76M1.45M
Total Non-current Liabilities69.58M116.56M81.03M74.47M73.62M
Total Liabilities170.63M244.28M165.94M145.87M123.37M
Common Stock101K110K15K28K32K
Retained Earnings(547.46M)(634.23M)(694.87M)(740.87M)(734.05M)
Accumulated OCI00000
Other Stockholders Equity0(103K)000
Minority Interest117.2M8.3M(20.96M)(24.38M)12.31M
Total Equity225.88M50.03M1.59M(1.64M)62.18M
Total Debt74.98M127.34M84.66M75.96M74.3M
Net Debt(230.77M)(50.92M)3.73M18.7M(5.08M)

Fortress Biotech, Inc.

NASDAQ:FBIO

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.